U.S. FDA to Review Compounded Peptides as Gray Medical Market Reaches a Regulatory Crossroads

In the United States, peptides have long since moved beyond laboratory papers and fitness forums. They are being packaged as prescription options for tissue repair, inflammation control, metabolic improvement, or modulation of neurological function, entering consumers’ view through compounding pharmacies and telemedicine services. Newly released advisory meeting materials from the U.S. Food and Drug Administration (FDA) have formally brought this market, which has long moved between medical need, commercial promotion, and evidence gaps, before public scrutiny.

The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24, 2026, to discuss whether several peptide bulk drug substances may be included on the bulk drug substances list under Section 503A of the Federal Food, Drug, and Cosmetic Act. If a specific ingredient is placed on the list, eligible traditional compounding pharmacies may be more likely to use that raw material to prepare drugs on the basis of individual prescriptions; however, a committee recommendation itself is not the same as a final FDA decision.

The ingredients included for discussion this time include BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax, and Epitalon. The proposed uses presented in the FDA meeting materials are quite dispersed, covering ulcerative colitis, wound healing, obesity, osteoporosis, insomnia, opioid withdrawal, and several neurological-related conditions. This breadth is one of the core controversies: the more diseases that are folded into the messaging, the more clearly it must be answered whether human evidence, dosing, quality, and long-term risks can keep pace.

Take BPC-157 as an example. FDA briefing documents on BPC-157 free base and BPC-157 acetate state that neither has an applicable USP or NF drug substance monograph, and neither is a component of any FDA-approved drug. The documents also conclude that the existing evaluation criteria do not support adding these two forms to the 503A list, citing reasons including insufficient evidence of effectiveness, insufficient safety data, limited historical experience with compounding, and remaining questions about the characterization of their physicochemical properties.

The review of KPV also shows a similarly conservative tone. FDA documents indicate that the nominated KPV compounded products were 0.1% topical creams and gels, promoted for wound healing and inflammation-related uses; although the nomination was later withdrawn, FDA still independently evaluated KPV free base and KPV acetate. That document likewise concludes that the existing criteria do not favor including these ingredients on the 503A list, showing that the regulator has not lowered its evidence requirements because market demand has heated up.

The Guardian’s reporting on the same meeting adds the tension at the industry and public health levels: if restrictions are loosened, U.S. compounding pharmacies and telemedicine providers may find it easier to prescribe and supply some peptides; critics, meanwhile, worry that without solid human safety and efficacy data, consumers may misread early research, animal experiments, or anecdotal experience as mature treatment. These concerns may not apply to all peptides, but they are enough to explain why regulatory review cannot look only at market enthusiasm.

The significance of this meeting, therefore, is not only whether a few ingredients can enter a list. It will test how the FDA draws the line between “patients and physicians need flexibility for individualized medication” and “unapproved products should not bypass safety and effectiveness thresholds.” For the biopharmaceutical industry, peptides may still be an important drug platform; but before they become trusted treatments, they still need support from clinical evidence that is reproducible, reviewable, and capable of tracking adverse reactions.